Business
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue Expanded adjusted gross margin to 71%
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\n\nReported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue\n\n\n\nExpanded adjusted gross margin to 71% and generated adjusted net income1 of $15.0 million for the second quarter 2025\n\n\n\nRaised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue\n\n\n\nAnnounced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability\n\n\n\nHosting conference call today at 8:30 a.m. ET\n\n\n\n GAITHERSBURG, Md.--(BUSINESS WIRE)--\nGeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025.\n\n\n“Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more patients while reducing unnecessary spend across the global healthcare system,” said Katherine Stueland, CEO of GeneDx. “Our strong second quarter performance was driven by our core business, underscoring its strength and resilience. These results, coupled with the ever-expanding opportunities ahead, including general pediatrics, demonstrate that we’re just beginning to deliver on the promise of how our technology can fundamentally change the way genomics can inform healthcare, shifting from reactive to proactive care.”\n\n\nSecond Quarter 2025 Financial Results (Unaudited)1,2\n\n\nRevenues\n\n\n\nRevenues grew to $102.7 million, an increase of 49% year-over-year.\n\n\n\nExome and genome test revenue grew to $85.9 million, an increase of 69% year-over-year.\n\n\n\nExome and genome volume\n\n\n\nExome and genome test results volume grew to 23,102, an increase of 28% year-over-year.\n\n\n\nExome and genome represented 41% of all tests, up from 31% in the second quarter of 2024.\n\n\n\nGross margin\n\n\n\nAdjusted gross margin expanded to 71%, up from 62% in the second quarter of 2024.\n\n\nTotal GAAP gross margin was 69%.\n\n\n\n\n\n\nOperating expenses\n\n\n\nAdjusted total operating expenses were $57.8 million, representing 56% of revenue in the second quarter of 2025,...